Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin vs metformin + ezetimibe for non-alcoholic fatty liver disease
IRCT20090305001745N3Phase 3Completed
- Sponsor
- Shahrood Islamic Azad University
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of metformin and ezetimibe in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shahrood Islamic Azad University. Started Dec 2023; status: completed.
02
Drugs
metforminezetimibe
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20090305001745N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090305001745N3.